Bristol-Myers Squibb

Yahoo Finance • 19 hours ago

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highli... Full story

Yahoo Finance • 19 hours ago

Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs über verschiedene PD-L1-Expressi... Full story

Yahoo Finance • 4 days ago

This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative.

BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Da... Full story

Yahoo Finance • 4 days ago

Kardigan targets IPO to support cardiology pipeline progression

Just under a year and a half after its debut, Kardigan is eyeing a listing on the Nasdaq to support the continued development of its in-licensed cardiology pipeline – adding another name to the burgeoning list of American biotechs undertak... Full story

Yahoo Finance • 5 days ago

Bristol Myers Squibb ASCO Data Puts Oncology Pipeline In Investor Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bristol-Myers Squibb (NYSE:BMY) plans to present extensive new clinical data at the 2026 ASCO An... Full story

Yahoo Finance • 5 days ago

Thinning revenues: inside the $14bn Eliquis patent cliff

Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent expiries expected this year for Europe and in 2027 for the US and Japan. With global sales of $... Full story

Yahoo Finance • 5 days ago

China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says

By Andrew Silver SHANGHAI, May 26 (Reuters) - China's booming pharmaceutical industry is not being impacted by Beijing's ‌tightening scrutiny over deals involving sensitive technologies, ‌the CEO of JW Therapeutics said Tuesday. Global d... Full story

Yahoo Finance • 6 days ago

Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight

DelveInsight Business Research LLP The multiple myeloma market is evolving toward immunotherapy-dominated, multi-line treatment paradigms with strong growth driven by CAR-T and bispecific antibodies. Leading contenders advancing through t... Full story

Yahoo Finance • 6 days ago

1 Surging Stock with Promising Prospects and 2 We Ignore

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance. However, not all companies... Full story

Yahoo Finance • 7 days ago

Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.

Key Points Bristol Myers Squibb faces a daunting patent cliff. The company has a promising growth portfolio, but it may not be able to fully offset losses from older drugs. Income investors and patient investors who aren't risk-averse cou... Full story

Yahoo Finance • 8 days ago

Fed Hawks Now Rule. Will Warsh Go Along with Them?

As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX. Continue Reading... Full story

Yahoo Finance • 9 days ago

Catalyst Watch: Fedspeak ramps up post-Powell, core PCE, and box office blitz

[Business Stock Exchange Trading Concepts] Rawpixel Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDA... Full story

Yahoo Finance • 9 days ago

Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields

Quick Read Vanguard Dividend Appreciation ETF (VIG) yields just 1.6% but delivered 247% returns over a decade by capturing dividend growers including Microsoft (MSFT) at 3.94% of holdings and Johnson & Johnson (JNJ) at significant weight,... Full story

Yahoo Finance • 9 days ago

1 Profitable Stock to Keep an Eye On and 2 We Brush Off

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. A business making money today isn’t nece... Full story

Yahoo Finance • 11 days ago

BioArctic AB (BRCTF) Q1 2026 Earnings Call Highlights: Strong Sales and Strategic Partnerships ...

This article first appeared on GuruFocus. Release Date: May 20, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BioArctic AB (BRCTF) reported strong financial re... Full story

Yahoo Finance • 11 days ago

Bristol-Myers taps Anthropic's Claude for 30,000 workers: report

Bristol-Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) is bringing Anthropic’s (ANTHRO [https://seekingalpha.com/symbol/ANTHRO]) flagship Claude product to more than 30,000 of its employees—deepening its use of artificial intelli... Full story

Yahoo Finance • 11 days ago

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

The collaboration brings together BMS’ deep scientific expertise and Anthropic's frontier AI to accelerate the discovery, development and delivery of transformational medicines BMS will deploy Claude's agentic capabilities, moving beyond... Full story

Yahoo Finance • 12 days ago

Bristol Myers Squibb Expands US Capacity And Trials With Houston Moves

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Bristol Myers Squibb (NYSE:BMY) is investing US$1b in a new manufacturing facility in Houston, aimed at expanding pharmaceutical p... Full story

Yahoo Finance • 12 days ago

Update: Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

(Updates with Novo Nordisk's response in the fourth and fifth paragraphs.) The US Supreme Court o PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n... Full story

Yahoo Finance • 13 days ago

TrumpRx set to expand into generic medicines with Mark Cuban

Heather Diehl/Getty Images News * Mark Cuban, the billionaire co-founder of the Cost Plus Drugs online pharmacy, is expected to join President Trump Monday afternoon as part of an announcement that the TrumpRx website will now carry gen... Full story